CLINICAL TRIALS PROFILE FOR CURRETAB

All Clinical Trials for CURRETAB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00064025 ↗	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	National Cancer Institute (NCI)	Phase 2	2004-04-01	This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
NCT00064025 ↗	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	Gynecologic Oncology Group	Phase 2	2004-04-01	This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
NCT00577122 ↗	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer	Completed	Translational Breast Cancer Research Consortium	Phase 2	2007-07-01	The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
NCT00577122 ↗	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer	Completed	Indiana University	Phase 2	2007-07-01	The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.

Clinical Trial Conditions for CURRETAB

Condition Name

Condition Name for CURRETAB
Intervention	Trials
Stage IV Uterine Corpus Cancer	1
Endometrial Adenosquamous Carcinoma	1
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation	1
Estrogen Receptor-negative Breast Cancer	1

Condition MeSH

Condition MeSH for CURRETAB
Intervention	Trials
Carcinoma, Adenosquamous	1
Carcinoma	1
Adenocarcinoma	1
Breast Neoplasms	1

Clinical Trial Locations for CURRETAB

Trials by Country

Trials by Country for CURRETAB
Location	Trials
United States	7

Trials by US State

Trials by US State for CURRETAB
Location	Trials
Texas	1
North Carolina	1
Massachusetts	1
Indiana	1
California	1

Clinical Trial Progress for CURRETAB

Clinical Trial Phase

Clinical Trial Phase for CURRETAB
Clinical Trial Phase	Trials
Phase 2	2

Clinical Trial Status

Clinical Trial Status for CURRETAB
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for CURRETAB

Sponsor Name

Sponsor Name for CURRETAB
Sponsor	Trials
National Cancer Institute (NCI)	1
Gynecologic Oncology Group	1
Translational Breast Cancer Research Consortium	1

Sponsor Type

Sponsor Type for CURRETAB
Sponsor	Trials
Other	3
NIH	1

Last updated: April 24, 2026

Clinical trials update, market analysis and projection for CURRETAB

What is CURRETAB’s current clinical development status?

No complete, verifiable clinical trial record for a drug marketed or developed under the name “CURRETAB” is available in the information provided in this session.

What are the key clinical trial identifiers (NCT/EudraCT), phases, endpoints, and timelines?

No verifiable trial identifiers, phases, endpoints, enrollment status, or readout dates for CURRETAB are present in the information provided in this session.

How is the commercial opportunity shaped by indication, patient population, and competitive intensity?

No indication, target, mechanism of action, dosing form, geography, pricing, or competitor set for CURRETAB is present in the information provided in this session, which prevents a market sizing model tied to real-world demand drivers.

What is the market size and share projection for CURRETAB (by year)?

No product profile, launch geography, forecast assumptions, or comparable precedent products are present in the information provided in this session, so a numerical revenue projection for CURRETAB cannot be produced.

What is the competitive landscape and pricing pressure?

No competitors, therapeutics class, efficacy/safety differentiation, formulary status, or reimbursement pathway for CURRETAB is present in the information provided in this session.

---

Key Takeaways

• This session contains no verifiable data to build a clinical trials update or any market sizing and revenue projection for CURRETAB.
• No indication, trial identifiers, endpoints, or competitive context are provided, so a business-grade forecast cannot be constructed from facts.

---

FAQs

1. Is there a public clinical trial registry record for CURRETAB?
   Not available in this session’s information.

2. What phase is CURRETAB in and when are the next readouts?
   Not available in this session’s information.

3. What is the likely indication and patient population for CURRETAB?
   Not available in this session’s information.

4. How large is the market and what is the forecasted revenue trajectory?
   Not available in this session’s information.

5. Who are the main competitors and what pricing pressure should be expected?
   Not available in this session’s information.

---

References

[1] No sources were provided in this session.